Indication | Global Market Size |
Pre Clinical |
Phase Ib |
Phase IIb |
Potential support for EU Conditional Marketing Approval Submission |
Post EU Marketing US Phase 3 |
|
---|---|---|---|---|---|---|---|
Organ failure associated with Sepsis | $33B | Completed | Randomized, controlled Phase II ongoing |
Top-line data for Phase II April 24’ | |||
Moderate knee osteoarthritis | $7B | Randomized, controlled Phase I/II expected Q1 2024 |
Top-line data for Phase I/II Q3-25’ | ||||
End-stage knee osteoarthritis | $2B | Phase I/II ongoing |
Top-line data for Phase I/II EOQ3-24’ | ||||
Pipelineoribsn2024-02-26T15:05:26+03:00